Current Report Filing (8-k)
February 06 2023 - 9:01AM
Edgar (US Regulatory)
0001445815
false
0001445815
2023-01-27
2023-01-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 27, 2023
BIOXYTRAN,
INC.
(Exact
Name if Business Issuer as specified in its Charter)
Nevada |
|
001-35027 |
|
26-2797630 |
(State or other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification Number) |
75,
Second Avenue,
Suite 605
Needham
MA, 02494
(Address
of principal executive offices, including zip code)
(617)
494-1199
(Registrant’s
telephone number including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 1 4a- 12 under the Exchange Act (17 CFR 240.1 4a- 12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 1 4d-2(b) under the Exchange Act (17 CFR 240.1 4d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 1 3e-4(c) under the Exchange Act (17 CFR 240.1 3e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
|
|
|
|
Common
Stock, par value $0.001 |
|
BIXT |
|
OTCPK |
Item
8.01 Other Events.
On
January 27, 2023, Bioxytran (the “Company”) has through India’s Central Drugs Standard Control Organisation (CDSCO)
received permission in form CT -06, No. CT/ND/03/2023, under the provisions of New Drugs and Clinical Trial Rules, 2019, to conduct:
“First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ProLectin-I Injection”
with the registration F. No. IND/CT/22/000078.
A
condition for the permission is that the clinical trial at each site shall be initiated after approval of the clinical trial protocol
and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority.
In
connection of with the above approval the Company issued on February 6, 2023 a press-release over Newswire, under the title:
Bioxytran
Receives Approval to Initiate Trials with ProLectin-I
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
By:
|
/s/
David Platt |
|
Name:
|
Dr.
David Platt |
|
Title:
|
President
and Chief Executive Officer |
|
|
|
|
Dated: |
February
6, 2023 |
Bioxytran (QB) (USOTC:BIXT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Bioxytran (QB) (USOTC:BIXT)
Historical Stock Chart
From Aug 2023 to Aug 2024